Cystic Fibrosis Foundation Announces Irena Barisic as Next Chief Operating...
BETHESDA, MD. - Today, the Cystic Fibrosis Foundation announced that Irena Barisic has been appointed the next Executive Vice President, Chief Operating and Financial Officer. Ms. Barisic will...
View ArticleCF Foundation and Bakar Labs Announce Winners of First-Ever Golden Ticket...
The Foundation and Bakar Labs will support AVECRIS Pte Ltd and Nosis Biological Sciences as they pursue genetic therapies for cystic fibrosis with their novel technologies.read more
View ArticleCystic Fibrosis Foundation Awards Up to $3.5M to Arrevus Inc. to Develop...
Pulmonary exacerbations are a sudden worsening of respiratory symptoms caused by lung infections that often require IV antibiotic treatment.read more
View ArticleCystic Fibrosis Foundation Announces Investment in SalioGen Therapeutics to...
BETHESDA, Md. -- The Cystic Fibrosis Foundation announced today that it has invested in SalioGen Therapeutics to support the company’s preclinical research into a novel genetic therapy for cystic...
View ArticleCF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy
BETHESDA, Md. -- The Cystic Fibrosis Foundation announced today that it has awarded up to $5 million to BiomX Inc.read more
View ArticleCF Foundation Awards Up to $4.7M to EnBiotix Inc. to Develop Inhaled...
Although it is approved in Europe, inhaled colistin is not approved for use in the U.S. Currently, the only approved inhaled antibiotics in the U.S. are tobramycin and aztreonam. However, many people...
View ArticleCF Foundation Awards More Than $1.8M to Three Companies for Genetic Therapies...
The Cystic Fibrosis Foundation announced today that it has awarded more than $1.8 million to three companies for early-stage research into potential genetic therapies for cystic fibrosis as part of its...
View ArticleCF Foundation Invests $3.5 Million in Pulmocide for Development of Novel...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced its investment of $3.5 million in Pulmocide Limited, a U.K.-based biotech company, to develop an inhaled drug (opelconazole) to prevent...
View ArticleCystic Fibrosis Foundation Strikes First-of-Its-Kind Deal With Pioneering...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced a first-of-its-kind collaboration with Pioneering Medicines, an initiative of Flagship Pioneering, to spur the development of genetic...
View ArticleCF Foundation Commits up to $14 Million in Funding to Expand Research...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced it is expanding its research collaboration with Synspira Therapeutics Inc., committing up to $14 million in additional funding to...
View ArticleCF Foundation Launches Lung Transplant Biorepository and Patient Registry
Today, the Cystic Fibrosis Foundation announced the launch of a first-of-its-kind Cystic Fibrosis Lung Transplant Consortium (CFLTC) Biorepository and Registry. The CFLTC Biorepository and Patient...
View ArticleCF Foundation Announces 2021 Impact Grant Recipients
The Cystic Fibrosis Foundation today announced the recipients of its sixth annual Impact Grants, which provide up to $10,000 of funding per year for up to two years to individuals and nonprofit...
View ArticleCystic Fibrosis Foundation Announces Changes on Board of Trustees
Today, the Cystic Fibrosis Foundation announced changes on its Board of Trustees, including the election of Jessica Boyd, MD; Dominic J. Caruso; and Paul Motenko as Trustees. James R. Butler, II; Eric...
View ArticleU.S. Supreme Court Rules on the Affordable Care Act
Today, the United States Supreme Court issued a decision in California v. Texas, dismissing the case and ultimately protecting key provisions of the Patient Protection and Affordable Care Act...
View ArticleCF Foundation Launches New Collaboration to Overcome Challenges to Developing...
BETHESDA, Md. -- Today, the CF Foundation announced a new collaboration with venture creator Deep Science Ventures, focused on uncovering and designing new technologies with the potential to overcome...
View ArticleFirst-of-Its-Kind Study Uses Smartphone to Track Cystic Fibrosis in Real Life
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced the initiation of the HERO-2: Home Reported Outcomes Study, a first-of-its-kind, at-home observational study that aims to characterize...
View ArticleCF Foundation Funds Three New Research Awards to Advance its Path to a Cure...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced three new research awards as part of its Path to a Cure initiative to accelerate the development of treatments for the underlying cause...
View ArticleCF Foundation Invests Up to $8.4M in SpliSense for the Development of...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide (ASO) therapy for...
View ArticleCF Foundation Responds to NIH Call for Information on Diversity and Inclusion
Cystic fibrosis affects people of different racial and ethnic backgrounds. As of 2019, nearly five percent of people with CF in the U.S. identify as Black and nearly 10 percent identify as Hispanic....
View ArticleWilliam Skach, Chief Scientific Officer, to Retire From the CF Foundation
In 2014, Dr. Skach joined the CF Foundation to oversee the Foundation's investments in basic research and venture philanthropy programs at a pivotal time for CF science. Under his leadership, the...
View Article
